Please login to the form below

Not currently logged in
Email:
Password:

DPP-4 inhibitors

This page shows the latest DPP-4 inhibitors news and features for those working in and with pharma, biotech and healthcare.

FDA rejects AZ's diabetes combination

FDA rejects AZ's diabetes combination

DPP-4 inhibitors are already widely used in diabetes and SGLT2 inhibitors are fast gaining ground, despite some initial concerns about safety. ... SGLT2 inhibitors remove glucose through the urine by blocking blood glucose re-absorption in the kidney,

Latest news

  • Merck gets first OK for once-weekly DPP-4 inhibitor Merck gets first OK for once-weekly DPP-4 inhibitor

    and showed that the drug is as effective at controlling blood glucose as daily DPP-4 inhibitors. ... Not all are convinced of the benefit of this approach however, particularly as most patients taking DPP-4 inhibitors also take metformin.

  • Jardiance is first diabetes drug to improve CV outcomes Jardiance is first diabetes drug to improve CV outcomes

    It will also help to offset some of the negative impact of an FDA warning earlier this year that SGLT2 inhibitors may be linked to high levels of blood acids that ... However, the DPP-4 inhibitors have so far been unable to show an improvement on

  • Type 2 diabetes market set to hit $39bn by 2021 Type 2 diabetes market set to hit $39bn by 2021

    In particular its new report points to three classes of drugs: dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium– glucose cotransporter 2 inhibitors. ... DPP-4 inhibitors are already a widely-used

  • Novo Nordisk becomes diabetes drug sales leader Novo Nordisk becomes diabetes drug sales leader

    New deals. AZ is by far the largest growth driver in the top 15 list thanks predominately to sales of its type II medicine DPP-4 medicine Onglyza(saxagliptin), which saw ... The FDA recently asked for more information of the DPP-4 inhibitors in

  • Merck & Co's diabetes drug Januvia cleared by CV safety trial Merck & Co's diabetes drug Januvia cleared by CV safety trial

    The CV safety of diabetes drugs, and DPP-4 inhibitors like Januvia, has been put under close scrutiny after signals of a possible negative impact on cardiovascular health were observed in ... Earlier this year FDA advisers recommended two DPP-4 inhibitors

More from news
Approximately 2 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2013 Pharma deals during April 2013

    standalone product and in combination with other drugs, including Januvia (Merck's blockbuster DPP-4 inhibitor) and metformin. ... SGLT2 inhibitors block the reabsorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics